"I aspire to innovate at the interface between biology and technology with the hope to address unmet medical needs."
I joined Genentech in 2020 as Vice President, Large Molecule Drug Discovery. I was attracted to Genentech because of its reputation, scientific rigor, and rich legacy in large molecule drug discovery and development.
The large molecule discovery team collaborates with therapeutic area biology, functional, and early development teams to establish and progress a potentially impactful therapeutics portfolio.
Nature. 2019 Oct;574(7779):565- 570. doi: 10.1038/s41586-019-1674-5.
My research is focussed on using protein engineering to modulate biological mechanisms of diseases. In the past, it has included site-specifically conjugated ADCs, bispecific IgG, and cell therapies in oncology; conditionally activated molecules in cancer immunology and metabolic diseases; patient derived neutralizing antibodies against infectious pathogens; and directed evolution of alternative scaffolds in neuroscience.